glp-1 nad+ Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update Unlocking Synergy: How NAD+ Injections

Studies have shown the propensity for inaccuracy in coding for DR, 28 particularly after hospital systems switched from ICD-9 to ICD-10 coding, 29 and a recent study highlighted the difference in coding for DR severity between retina specialists and general ophthalmologists

As a busy man focused on your career, we know your time is limited

The journey to metabolic health is a marathon, not a sprint

The present review ultimately weighs early concerns against increasingly consistent evidence that GLP-1 RA use does not raise overall cancer risk, clarifies that breast cancer risk appears neutral, and further highlights key mechanisms, such as the reduction of hyperinsulinemia and immune-microenvironment modulation, through which these drugs may improve rather than exacerbate malignancy outcomes

Weeks 3-4: Gut microbiome begins shifting toward beneficial SCFA-producing bacteria

Find out more in this blog post on insulin resistance